QGEN

QIAGEN N.V.

50.33

USD

-0.53

-1.04%

Nov 06, 15:59 UTC -5

Closed

After-Market

50.31

-0.02

-0.04%

QIAGEN N.V. (QGEN) Earnings

QGEN Earnings Reports

Positive Surprise Ratio

QGEN beat 33 of 43 last estimates.

77%

Next Report

Date of Next Report

Feb 02, 2027

Estimate for Q4 26 (Revenue/ EPS)

$584.80M

$0.66

Implied change from Q3 26 (Revenue/ EPS)

+6.71%

+1.54%

Implied change from Q4 25 (Revenue/ EPS)

+8.21%

+6.45%

QIAGEN N.V. earnings per share and revenue

On Oct 21, 2026, QGEN reported earnings of 0.65 USD per share (EPS) for Q3 26, beating the estimate of 0.63 USD, resulting in a 2.43% surprise. Revenue reached 548.00 million, compared to an expected 548.00 million, with a 0.00% difference. The market reacted with a +0.44% price change (close before vs. close after earnings).

Looking ahead to Q4 26, -- analysts forecast an EPS of 0.66 USD, with revenue projected to reach 584.80 million USD, implying an increase of 1.54% EPS, and increase of 6.71% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Moderna, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$1.27

Actual

$0.38

Surprise

+129.79%

Genmab A/S ADS

Report Date

Nov 05, 2026 For Q3 26

Estimate

$3.86

Actual

$5.64

Surprise

+46.11%

Celcuity Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$1.46

Actual

-$1.33

Surprise

+9.05%

Certara, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.09

Actual

$0.09

Surprise

-0.88%

Castle Biosciences, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.37

Actual

-$0.13

Surprise

+65.32%

Corvus Pharmaceuticals, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.20

Actual

-$0.22

Surprise

-7.06%

Ginkgo Bioworks Holdings, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.87

Actual

-$0.64

Surprise

+27.17%

Lexicon Pharmaceuticals, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.05

Actual

-$0.03

Surprise

+49.41%

Tectonic Therapeutic, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$1.35

Actual

-$1.08

Surprise

+20.37%

SAB Biotherapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.24

Surprise

+12.85%

FAQ

What were QIAGEN N.V.'s earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, QIAGEN N.V. reported EPS of $0.65, beating estimates by 2.43%, and revenue of $548.00M, 0% as expectations.

How did the market react to QIAGEN N.V.'s Q3 2026 earnings?

The stock price moved up 0.44%, changed from $50.00 before the earnings release to $50.22 the day after.

When is QIAGEN N.V. expected to report next?

The next earning report is scheduled for Feb 02, 2027.

What are the forecasts for QIAGEN N.V.'s next earnings report?

Based on -- analysts, QIAGEN N.V. is expected to report EPS of $0.66 and revenue of $584.80M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.